Next Article in Journal
Anti-Epileptic Effects of FABP3 Ligand MF1 through the Benzodiazepine Recognition Site of the GABAA Receptor
Next Article in Special Issue
IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer
Previous Article in Journal
Emerging Role of Extracellular Vesicles in Embryo–Maternal Communication throughout Implantation Processes
Previous Article in Special Issue
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
Open AccessArticle

NR2F6 as a Prognostic Biomarker in HNSCC

1
Institute of Pathology, University of Luebeck and University Hospital Schleswig-Holstein, 23538 Luebeck, Germany
2
Department of Otorhinolaryngology, University of Luebeck and University Hospital Schleswig-Holstein, Campus Luebeck, 23538 Luebeck, Germany
3
Department of Radiation Oncology, University of Luebeck and University Hospital Schleswig-Holstein, 23538 Lübeck, Germany
4
Department of Otorhinolaryngology, MRI Technical University Munich, 81675 Munich, Germany
5
Pathology, Research Center Borstel, Leibniz Lung Center, 23845 Borstel, Germany
*
Author to whom correspondence should be addressed.
These authors have contributed equally.
These authors have contributed equally.
Int. J. Mol. Sci. 2020, 21(15), 5527; https://doi.org/10.3390/ijms21155527
Received: 23 June 2020 / Revised: 23 July 2020 / Accepted: 30 July 2020 / Published: 1 August 2020
Head and neck squamous cell carcinoma (HNSCC)is the 6th most common cancer in humans worldwide and is associated with a poor prognosis for patients. NR2F6 has been identified as an immune checkpoint molecule in tumor-infiltrating T lymphocytes and is associated with a poor prognostic outcome in various cancers. The prognostic value of NR2F6 in HNSCC has not been described yet. We used a large, representative and clinically well-characterized cohort of 383 HNSCC patients, of which 22.4% developed a local recurrence. The NR2F6 expression was analyzed by using immunohistochemistry and was afterward correlated with clinical characteristics and clinicopathological features of HNSCC patients. Primary tumors from patients who develop a local recurrence have a higher NR2F6 expression than primary tumors which do not develop a local recurrence. Furthermore, a high NR2F6 expression is associated with poorer recurrence-free survival, although there is no correlation with overall survival. NR2F6 expression is independent of the T stage and UICC stage. NR2F6 might be a new prognostic biomarker for the early detection of local recurrences in HNSCC patients. Therefore, it may help to improve the recognition of patients who would benefit from more frequent follow-up examinations. View Full-Text
Keywords: HNSCC; NR2F6; local recurrence; prognosis; recurrence-free survival; biomarker; immune checkpoint; TMA; FFPE HNSCC; NR2F6; local recurrence; prognosis; recurrence-free survival; biomarker; immune checkpoint; TMA; FFPE
Show Figures

Figure 1

MDPI and ACS Style

Klapper, L.; Ribbat-Idel, J.; Kuppler, P.; Paulsen, F.-O.; Bruchhage, K.-L.; Rades, D.; Offermann, A.; Kirfel, J.; Wollenberg, B.; Idel, C.; Perner, S. NR2F6 as a Prognostic Biomarker in HNSCC. Int. J. Mol. Sci. 2020, 21, 5527.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop